438 related articles for article (PubMed ID: 21377143)
21. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.
Kim JL; Kang MK; Gong JH; Park SH; Han SY; Kang YH
Mol Nutr Food Res; 2012 Aug; 56(8):1223-33. PubMed ID: 22700286
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting wear particles-induced osteolysis with doxycycline.
Zhang C; Tang TT; Ren WP; Zhang XL; Dai KR
Acta Pharmacol Sin; 2007 Oct; 28(10):1603-10. PubMed ID: 17883947
[TBL] [Abstract][Full Text] [Related]
23. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of RANKL-induced MITF-E expression and osteoclastogenesis by TGF-β.
Asai K; Funaba M; Murakami M
Cell Biochem Funct; 2014 Jul; 32(5):401-9. PubMed ID: 24519885
[TBL] [Abstract][Full Text] [Related]
25. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
26. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
29. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells.
Notoya M; Otsuka E; Yamaguchi A; Hagiwara H
Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477
[TBL] [Abstract][Full Text] [Related]
30. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
31. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
[TBL] [Abstract][Full Text] [Related]
32. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
33. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
34. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
35. TNF Induction of NF-κB RelB Enhances RANKL-Induced Osteoclastogenesis by Promoting Inflammatory Macrophage Differentiation but also Limits It through Suppression of NFATc1 Expression.
Zhao Z; Hou X; Yin X; Li Y; Duan R; Boyce BF; Yao Z
PLoS One; 2015; 10(8):e0135728. PubMed ID: 26287732
[TBL] [Abstract][Full Text] [Related]
36. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
37. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.
Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J
J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045
[TBL] [Abstract][Full Text] [Related]
38. The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.
Kogawa M; Hisatake K; Atkins GJ; Findlay DM; Enoki Y; Sato T; Gray PC; Kanesaki-Yatsuka Y; Anderson PH; Wada S; Kato N; Fukuda A; Katayama S; Tsujimoto M; Yoda T; Suda T; Okazaki Y; Matsumoto M
J Biol Chem; 2013 Oct; 288(43):31299-312. PubMed ID: 23990468
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
40. [Effect of naringin on osteoclast differentiation].
Li FB; Sun XL; Ma JX; Zhang Y; Zhao B; Li YJ; Ma XL
Zhongguo Zhong Yao Za Zhi; 2015 Jan; 40(2):308-12. PubMed ID: 26080564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
